| Objective: | To evaluate the safety and effectiveness of the TAXUS® Liberté-SR Paclitaxel-Eluting Coronary Stent System for the treatment of de novo lesions. |
| Number of Patients: | 871 enrolled patients (991 patients in historical control) |
| Number of Sites: | 61 sites globally |
| Control: | Lesion matched cohort of TAXUS® Express®Stent and TAXUS®Express2™Stent patients from TAXUS IV and TAXUS V |
| Study Design: | Prospective, single arm |
| Lesion Type: | de novo |
| Lesion Size: | ≥10 to ≤28 mm lesion length |
| Stent Platform: | TAXUS® Liberté™ 8-32 mm lengths, 2.50-4.0 mm diameters |
| Release Kinetics: | Slow Release (SR) |
| Primary Endpoint: | 9-month TVR |
| Principal Investigator: | Mark Turco, MD and John Ormiston, MD |
